Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease
May 15, 2022 18:00 ET | Zenas BioPharma
WALTHAM, Mass. and SHANGHAI, China, May 15, 2022 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of...
Zenas BioPharma在华提交ZB001用于治疗甲状腺眼病的试验性新药申请
May 15, 2022 18:00 ET | Zenas BioPharma
马萨诸塞州沃尔瑟姆和中国上海, May 16, 2022 (GLOBE NEWSWIRE) -- Zenas...
Zenas BioPharma 在中國提交 ZB001 用於治療甲狀腺眼病的試驗新藥申請
May 15, 2022 18:00 ET | Zenas BioPharma
馬薩諸塞州華瑟姆和中國上海, May 16, 2022 (GLOBE NEWSWIRE) -- Zenas BioPharma (澤納仕生物醫藥), 一家致力於成為全球有需要患者的免疫療法開發和商業化領導者的全球性生物醫藥公司,今天宣佈已經向中國國家藥品監督管理局 (NMPA) 提交並獲得受理一項試驗新藥 (IND) 申請,用於啟動 ZB001治療甲狀腺眼病 (TED) 的 1/2...
North America Precision Medicine Market size to surpass $50bn by 2027, says Graphical Research
May 02, 2022 07:07 ET | Graphical Research
Pune, India, May 02, 2022 (GLOBE NEWSWIRE) -- As per a recent industry report put forward by Graphical Research, the North America precision medicine market is forecast to register its name in the...
Rafarma Pharmaceuticals strengthens its position in Central Asia
Nicosia, Cyprus, April 29, 2022 (GLOBE NEWSWIRE) -- Representatives of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) visited Uzbekistan and discussed the prospects for the company's development in the...
Dr. William Haseltine releases new book on Innate Immunity and Covid-19
March 16, 2022 13:37 ET | ACCESS Health International
New York, March 16, 2022 (GLOBE NEWSWIRE) -- In his latest book, bestselling author William A. Haseltine Ph.D. tells us that understanding our natural immunity to the SARS-CoV-2 virus is critical...
The iQ Group Global secures worldwide license for Harvard University’s eRapid technology for at-home diagnostic testing
March 08, 2022 08:00 ET | The iQ Group Global
SYDNEY, Australia, March 08, 2022 (GLOBE NEWSWIRE) -- Antisoma Therapeutics Pty. Ltd., a medical technology company and member of The iQ Group Global, today announced it has received a worldwide...
Fluidigm Announces Fourth Quarter and Full Year 2021 Financial Results 
February 17, 2022 17:43 ET | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Biosimilars in Immunology Prescriber Opinions Survey 2021 - Factors Influencing Choice of Prescribed Biosimilar Brands
January 20, 2022 05:58 ET | Research and Markets
Dublin, Jan. 20, 2022 (GLOBE NEWSWIRE) -- The "Prescriber Opinions on Biosimilars in Immunology" report has been added to's offering. This report covers the 7MM (United...
Zenas BioPharma Appoints Dr. John Orloff to Board of Directors
January 06, 2022 07:00 ET | Zenas BioPharma
BOSTON and SHANGHAI, China, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and delivery of immune-based...